Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APN01 for severe hospitalized COVID-19
2020-001172-15Phase 2Completed
- Sponsor
- APEIRON Biologics AG
- Start
- Mar 2020
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of alunacedase alfa in coronavirus disease 2019 (COVID-19), sponsored by APEIRON Biologics AG. Started Mar 2020; status: completed.
02
Drugs
alunacedase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001172-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001172-15.